retatrutide clinical trial weight loss data New Phase 3 just dropped π Eli Lilly's reported average approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats Retatrutide Before and After: Doctor
Description
What is still unclear, he adds, is whether the GLP-1s were causal in reducing cancer risk
GLP1 receptor sensitivity varies between people
Retatrutide is still investigational and not widely approved for clinical use, whereas Tirzepatide is already approved and more widely accessible
In addition, some dosages of these approved drugs are on Food and Drug Administrations Drug Shortage List, meaning that the available supply cannot meet the current demand
pmid:31833141 48
Jastreboff, A
